WO2003066101A1 - Préparation pour composées sensibles a l'oxydation et son procédé de fabrication - Google Patents
Préparation pour composées sensibles a l'oxydation et son procédé de fabrication Download PDFInfo
- Publication number
- WO2003066101A1 WO2003066101A1 PCT/FR2003/000386 FR0300386W WO03066101A1 WO 2003066101 A1 WO2003066101 A1 WO 2003066101A1 FR 0300386 W FR0300386 W FR 0300386W WO 03066101 A1 WO03066101 A1 WO 03066101A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mixture
- antioxidant
- preparation
- active compound
- preparation according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/23—Sulfur; Selenium; Tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/27—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/29—Titanium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
Definitions
- the present invention relates to a process for preventing the oxidation of an oxygen-sensitive compound in a medicinal and / or cosmetic preparation. It also relates to a preparation obtained in accordance with the above process as well as a manufacturing process. It applies in particular, but not exclusively, to compounds derived from 2,6-di-tert-bù ylphenol.
- 2,6-di-tert-butylphenol compounds in particular 3,5-di-tert-butyl-4-hydroxytoluene also called 2,6-di-tert-butyl-4-methylphenol or BHT (“Butylated hydroxytoluene”) or its derivatives such as 3,5-di-tert-butyl-4-hydroxybenzoic acid (BG4), octaoxyethylene glycol 3,5-di-tert-butyl-4-hydroxybenzoate ( AVF1) have antiviral properties against viruses with lipid envelopes (W. Snipes et al., Science, 1975, vol. 188, n ° 4183;.
- packaging has been envisaged in single-dose gelatin capsules in order to keep the ointment away from air and UV until it is used.
- a process using multiple phases proves to be much more complicated both in terms of the operating mode and of the apparatus required and with a result which is not always that expected and a relatively high cost.
- the use of nanoparticles so as to encapsulate BHT is not satisfactory because it is a complex, costly process which, in the present case, does not make it possible to encapsulate active products with a concentration sufficient.
- the object of the invention is to eliminate these drawbacks by proposing a flexible, rapid technique and without risk of oxidation for the active compound.
- the micronization may allow particles to be obtained for the preparation whose size will be between 0.1 and 2 microns and preferably less than 0.2 microns.
- the active compound may be a derivative of 2,6-di-tert-butylphenol. It may be present in an amount ranging from 1 to 10%, preferably 5% by weight of the total weight of the preparation.
- This preparation may be biphasic.
- the oily phase may comprise the active compound and the weak antioxidant while the strong antioxidant will be soluble in the aqueous phase.
- aqueous phase always contains a certain percentage of oxygen.
- the strong antioxidant will react first and therefore it is a residual amount of oxygen that will pass through the oily phase and meet the weak antioxidants. The latter will, as they fix the oxygen, aggregate in particular around the active compounds by forming a protective film. This process then makes it possible to keep the active compound over a long period without any other alteration than that, minimal, which may have taken place before aggregation.
- the strong antioxidant could be sodium disulfite. It may be present in an amount ranging from 0.05% to 0.1%, preferably 0.05% by weight of the total weight of the preparation.
- the weak antioxidants could be metal oxides such as oxides of zinc, titanium, aluminum ...
- the preparation may include two weak antioxidants, for example zinc oxide and titanium dioxide.
- the zinc oxide may be present in an amount ranging from 0.1% to 2%, preferably 0.5% by weight of the total weight of the preparation.
- the titanium dioxide may be present in an amount ranging from 5% to 10%, preferably from 5% by weight of the total weight of the preparation.
- the overall amount of weak antioxidant may be between 5.1 and 12%, preferably 5.5% by weight of the total weight of the preparation.
- oxides of zinc and titanium have the advantage of having anti-UV filter properties. These properties can be used not only to protect from sun burns but also in particular for the prevention of herpes attacks in predisposed subjects, it being understood that exposure to the sun is recognized as one of the triggering factors of herpes.
- the preparation may include other compounds having therapeutic properties such as propolis, tepescohuite extracts or even excipients such as antiseptics.
- composition formulation will be described below, by way of nonlimiting examples.
- Example 1 The composition is as follows:
- mixture A is heated to 70-75 ° C. Once the temperature has stabilized, the elements of the mixture A 'are added to the mixture A one by one, with vigorous stirring (5-10,000 rpm) generated by a turbine so as to avoid the risks of oxidation linked to the transient phase of temperature rise of compounds such as BHT. In addition, this is when the BHT is coated with zinc and titanium oxides and it is important that the oily particles are as fine as possible.
- the mixture B is heated to 70-75 ° C then it is incorporated in one go to the reaction mixture (hot oily phase) with slow stirring in order to carry out the key step which is a phase inversion.
- micronization must then be excellent with particles having a size between 0.1 and 2 microns, preferably less than 0.2 microns.
- the whole is then cooled to 60-65 ° C while maintaining slow stirring and then the mixture C is added.
- the mixture is then brought to a temperature of 40-45 ° C as quickly as possible by a coil system in which water circulates and placed around the tank, and the mixture D is added and the stirring continues until 'at a temperature of 25-30 ° C to obtain the desired emulsion, that is to say very fine and shiny.
- phase inversion combined with the speed of rotation of the turbine and then with a rapid drop in temperature make it possible to obtain a coating of the BHT with the oxides of zinc and titanium, a result which approximates the microencapsulation obtained with a multiple emulsion but here, instead of requiring a complex procedure, a single step is sufficient.
- mixture A is heated to 70-75 ° C, in a tank. Once the temperature has stabilized, the elements of the mixture A 'are added to the mixture A one by one under strong stirring (5-10,000 rpm) generated by a turbine so as to avoid the risks of oxidation linked to the phase transient temperature rise of compounds such as BHT.
- the mixture B is heated to 70-75 ° C then it is incorporated in one go with slow stirring into the reaction mixture (hot oily phase) in order to effect the phase inversion.
- the mixture is then brought to a temperature of 40-45 ° C as quickly as possible by a se ⁇ entin system in which water circulates and placed around the tank and the mixture D is added.
- the cooling of the mixture continues and, at 35 ° C, the components of the mixture E are inco ⁇ orated then the stirring continues until a temperature of 25-30 ° C to obtain the desired emulsion, that is to say say very fine and shiny.
- the first acute skin tolerance study was carried out on a group of ten adult volunteers after single application to the skin of the anterior side of an arm, under an occlusive dressing maintained for forty eight hours. This test was carried out according to the methodology of patch tests under occlusion.
- the group included seven female subjects and three male subjects aged 19 to 36 years with no history of intolerance or allergy to a cosmetic product, skin pathology and not taking any treatment that interferes with skin metabolism. .
- the product was applied pure, only once, to a surface of 50 mm of skin on the anterior surface of an arm of each volunteer, at a dose of approximately 0.02 ml impregnating a washer of filter paper deposited in the cup of the occlusive dressing.
- the product was kept in contact with the skin for forty-eight consecutive hours.
- I.I.M ⁇ erythematous ratings / number of subjects
- Acute ocular tolerance was also evaluated on reconstituted cornea SKLNETHIC model and on a rabbit eye.
- the product was evaluated as to its ability to induce cytopathic effects on corneas reconstituted by in vitro cell culture of transformed keratinocytes.
- Cell culture is generally recognized in the scientific literature as a very sensitive and reliable method for studying the cytotoxic potential of pharmaceutical, cosmetic or medical products.
- transformed human keratinocytes of the TR146 line When cultured at the air-liquid interface in a defined medium, transformed human keratinocytes of the TR146 line form an epithelial tissue without a horny layer resembling the cornea of the human eye.
- a sample of the product to be studied (30 ⁇ l) is placed on each of six equivalent reconstituted cornea cultures and spread out using a fine brush. Two cultures are then incubated at 37 ° C, 5% C0 2 for ten minutes, one hour, three hours and twenty four hours.
- Negative (buffered phosphate saline solution A) and positive (0.4% SDS for "sodium dodecyl sulfate" in solution A) control substances are sterile prepared and placed on two other cultures in parallel and these cultures are incubated for one and twenty four hours.
- a culture constituting a negative control which has received no treatment is incubated in parallel.
- the viability or necrosis of keratinocytes in the basal layer of cultures is detected by an MTT cell viability test.
- Cell viability is measured qualitatively after labeling with a vital dye.
- the MTT system measures the mitochondrial dehydrogenase activity of living cells.
- the key component is 3 - [4,5-dimethylthiazol-2-yl] -2,5-diphenyl tetrazolium bromide (MTT).
- MTT buffered saline solutions in the absence of phenol red, are yellow in color.
- the mitochondrial dehydrogenases of living cells cut the tetrazolium cycle, thus inducing the formation of MTT formazan powder crystals, insoluble in aqueous solutions.
- the crystals formed by the viable cells are trapped in polycarbonate filters serving as support for the epithelial cultures.
- the cultures become uniformly intense blue / pumpkin in color when viable, but remain white / yellow in color if there is cell necrosis.
- the negative control cultures must be blue / intense in color, proof of the viability of the cells of the basal layer after twenty four hours of contact, - the positive control cultures must be white, proof of cell necrosis from the first contact time.
- NI non-irritant
- TKI very slightly irritating
- TI very irritating
- the cellular viability of the cells constituting the cornea appeared complete after ten minutes, one hour, three hours of contact with the pure studied product. After twenty-four hours, almost total mortality was noted.
- the pure cream studied is very slightly irritating to the cells constituting the “reconstituted cornea” model in vitro.
- the product can be considered as slightly irritating to the eye of the rabbit.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Birds (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Anti-Oxidant Or Stabilizer Compositions (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003222364A AU2003222364A1 (en) | 2002-02-06 | 2003-02-04 | Preparation for oxidation-sensitive compounds and method for making same |
JP2003565524A JP4614262B2 (ja) | 2002-02-06 | 2003-02-04 | 酸素感受性化合物のための製剤及びその製造方法 |
CA2475218A CA2475218C (fr) | 2002-02-06 | 2003-02-04 | Preparation pour composes sensibles a l'oxydation et son procede de fabrication |
US10/503,360 US20050175644A1 (en) | 2002-02-06 | 2003-02-04 | Preparation for oxidation-sensitive compounds and method for making same |
EP03717383A EP1478402A1 (fr) | 2002-02-06 | 2003-02-04 | Preparation pour composees sensibles a l'oxydation et son procede de fabrication |
BR0307486-2A BR0307486A (pt) | 2002-02-06 | 2003-02-04 | Preparado para compostos sensìveis à oxidação e ao respectivo processo de fabricação |
IL163365A IL163365A (en) | 2002-02-06 | 2004-08-05 | Preparation containing oxidation - sensitive compounds and antioxidants and method for making same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR02/01456 | 2002-02-06 | ||
FR0201456A FR2835522B1 (fr) | 2002-02-06 | 2002-02-06 | Preparation pour composes sensibles a l'oxydation et son procede de fabrication |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003066101A1 true WO2003066101A1 (fr) | 2003-08-14 |
Family
ID=27619968
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2003/000386 WO2003066101A1 (fr) | 2002-02-06 | 2003-02-04 | Préparation pour composées sensibles a l'oxydation et son procédé de fabrication |
Country Status (10)
Country | Link |
---|---|
US (1) | US20050175644A1 (fr) |
EP (1) | EP1478402A1 (fr) |
JP (1) | JP4614262B2 (fr) |
AU (1) | AU2003222364A1 (fr) |
BR (1) | BR0307486A (fr) |
CA (1) | CA2475218C (fr) |
FR (1) | FR2835522B1 (fr) |
IL (1) | IL163365A (fr) |
WO (1) | WO2003066101A1 (fr) |
ZA (1) | ZA200406128B (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2418855A (en) * | 2004-06-28 | 2006-04-12 | Riba Fairfield Inc | Pharmaceutical grade ethyl lactate composition |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2867683B1 (fr) * | 2004-03-22 | 2012-12-21 | Lm Cosmetics | Compositions cosmetiques ou dermatologiques et leurs applications |
KR101340514B1 (ko) * | 2007-01-24 | 2013-12-12 | 삼성디스플레이 주식회사 | 박막 트랜지스터 기판 및 이의 제조 방법 |
FR2933616B1 (fr) * | 2008-07-10 | 2011-08-19 | Robert Vachy | "compositions renfermant une association de propolis et d'un derive phenolique et leurs applications biologiques" |
DE102009048977A1 (de) * | 2009-10-09 | 2011-04-14 | Beiersdorf Ag | Kosmetische oder dermatologische Zubereitungen mit Kombinationen aus 4-n-Butylresorcin und einem oder mehreren Sulfiten, insbesondere Hydrogensulfiten und/oder Disulfiten |
DE102009048974A1 (de) * | 2009-10-09 | 2011-04-14 | Beiersdorf Ag | Kosmetische oder dermatologische Zubereitungen mit Kombinationen aus öllöslichen kosmetischen oder dermatologischen Wirkstoffen und einem oder mehreren Sulfiten (Bisulfiten oder Disulfiten) |
CN104961166A (zh) | 2010-11-15 | 2015-10-07 | 阿彻丹尼尔斯米德兰德公司 | 组合物及其在转化污染物中的用途 |
KR102348583B1 (ko) * | 2020-04-29 | 2022-01-07 | 주식회사 닥터이엘 | 천연색소 변색방지용 조성물 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991013626A1 (fr) * | 1990-03-12 | 1991-09-19 | Fileco | Composition therapeutique contenant un compose phenol et de la propolis utile contre le virus a capside lipidique, notamment les virus de l'herpes |
WO1992010995A1 (fr) * | 1990-12-19 | 1992-07-09 | Beecham Group Plc | Nouvelles compositions |
EP0517274A1 (fr) * | 1991-06-07 | 1992-12-09 | Byk Nederland BV | Lavement pharmaceutique |
EP0586106A1 (fr) * | 1992-08-06 | 1994-03-09 | JOHNSON & JOHNSON CONSUMER PRODUCTS, INC. | Compositions pour le soin de la peau contenant des imidazoles et des rétinoides |
EP0992233A2 (fr) * | 1998-09-18 | 2000-04-12 | Beiersdorf Aktiengesellschaft | Systèmes en dispersion fine des types huile-dans-l'eau et eau-dans-l'huile sans émulsifiants |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4883654A (en) * | 1987-01-09 | 1989-11-28 | Young Deborah A | Cosmetic preparation |
ES2012104A6 (es) * | 1988-06-28 | 1990-03-01 | Perez Julio Tellez | Procedimiento para la extraccion y aislamiento del principio activo regenerador epidermal de la mimosa tenuiflora y composicion cosmetica que lo contiene. |
AU9020991A (en) * | 1990-11-12 | 1992-06-11 | Fileco | Antiviral use of a 2,6-di-t-butylphenol compound substituted in position 4, particularly in relation to herpesviruses and papillomaviruses |
FR2718639B1 (fr) * | 1994-04-18 | 1996-05-15 | Oreal | Composition cosmétique et/ou dermatologique contenant un tri (alpha-hydroxyacylate) de glycerol comme seul précurseur de glycerol. |
DE19539141B4 (de) * | 1995-10-20 | 2016-07-07 | Merck Patent Gmbh | 2,6-Di-tert.-butylphenole |
DE59804248D1 (de) * | 1997-03-25 | 2002-07-04 | Beiersdorf Ag | Emulgatorfreie feindisperse systeme vom typ wasser-in-öl |
DE19809304A1 (de) * | 1998-03-05 | 1999-09-09 | Merck Patent Gmbh | Formulierungen mit antiviraler Wirkung |
JPH11279046A (ja) * | 1998-03-30 | 1999-10-12 | Shiseido Co Ltd | 皮膚外用剤 |
-
2002
- 2002-02-06 FR FR0201456A patent/FR2835522B1/fr not_active Expired - Fee Related
-
2003
- 2003-02-04 BR BR0307486-2A patent/BR0307486A/pt not_active IP Right Cessation
- 2003-02-04 AU AU2003222364A patent/AU2003222364A1/en not_active Abandoned
- 2003-02-04 JP JP2003565524A patent/JP4614262B2/ja not_active Expired - Fee Related
- 2003-02-04 CA CA2475218A patent/CA2475218C/fr not_active Expired - Fee Related
- 2003-02-04 US US10/503,360 patent/US20050175644A1/en not_active Abandoned
- 2003-02-04 WO PCT/FR2003/000386 patent/WO2003066101A1/fr active Application Filing
- 2003-02-04 EP EP03717383A patent/EP1478402A1/fr not_active Withdrawn
-
2004
- 2004-07-30 ZA ZA200406128A patent/ZA200406128B/en unknown
- 2004-08-05 IL IL163365A patent/IL163365A/en not_active IP Right Cessation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991013626A1 (fr) * | 1990-03-12 | 1991-09-19 | Fileco | Composition therapeutique contenant un compose phenol et de la propolis utile contre le virus a capside lipidique, notamment les virus de l'herpes |
WO1992010995A1 (fr) * | 1990-12-19 | 1992-07-09 | Beecham Group Plc | Nouvelles compositions |
EP0517274A1 (fr) * | 1991-06-07 | 1992-12-09 | Byk Nederland BV | Lavement pharmaceutique |
EP0586106A1 (fr) * | 1992-08-06 | 1994-03-09 | JOHNSON & JOHNSON CONSUMER PRODUCTS, INC. | Compositions pour le soin de la peau contenant des imidazoles et des rétinoides |
EP0992233A2 (fr) * | 1998-09-18 | 2000-04-12 | Beiersdorf Aktiengesellschaft | Systèmes en dispersion fine des types huile-dans-l'eau et eau-dans-l'huile sans émulsifiants |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2418855A (en) * | 2004-06-28 | 2006-04-12 | Riba Fairfield Inc | Pharmaceutical grade ethyl lactate composition |
GB2418855B (en) * | 2004-06-28 | 2009-01-21 | Riba Fairfield Inc | Use of ethyl lactate as an excipient for pharmaceutical compositions |
Also Published As
Publication number | Publication date |
---|---|
AU2003222364A1 (en) | 2003-09-02 |
JP4614262B2 (ja) | 2011-01-19 |
FR2835522A1 (fr) | 2003-08-08 |
CA2475218C (fr) | 2012-09-11 |
CA2475218A1 (fr) | 2003-08-14 |
IL163365A (en) | 2008-07-08 |
ZA200406128B (en) | 2006-07-26 |
BR0307486A (pt) | 2004-12-07 |
FR2835522B1 (fr) | 2006-04-07 |
JP2005521677A (ja) | 2005-07-21 |
EP1478402A1 (fr) | 2004-11-24 |
US20050175644A1 (en) | 2005-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0447318B1 (fr) | Composition pour le traitement cosmétique et/ou pharmaceutique des couches supérieures de l'épiderme par application topique sur la peau et procédé de préparation correspondant | |
EP1438015B1 (fr) | Compositions cosmetiques et dermopharmaceutiques pour les peaux a tendance acneique | |
Pan-In et al. | Depositing α-mangostin nanoparticles to sebaceous gland area for acne treatment | |
EP1748758A1 (fr) | Formulation de type spot-on utile en cosmetologie et en dermatologie | |
EP1443940A1 (fr) | Composition pharmaceutique a base de progesterone micronisee, son procede de preparation et ses utilisations | |
FR2848847A1 (fr) | Composition cosmetique ou dermopharmaceutique comprenant une enzyme insoluble en milieu aqueux, ainsi que ses utilisations | |
EP0332478A1 (fr) | Liposomes contenant des extraits de Scutellaria | |
FR2956818A1 (fr) | Utilisation d'un hydrolysat peptidique de lin dans une composition pour apaiser la peau | |
EP0629397B1 (fr) | Composition cosmétique ou pharmaceutique anti-radicaux libres pour application topique | |
FR2664164A1 (fr) | Composition dermatologique ou cosmetique. | |
CA2475218C (fr) | Preparation pour composes sensibles a l'oxydation et son procede de fabrication | |
EP0318369B2 (fr) | Composition à base de phases lamellaires lipidiques hydratées ou de liposomes contenant de la tyrosine ou un dérivé de tyrosine et composition cosmétique ou pharmaceutique, notamment dermatologique, à activité pigmentante, l'incorporant | |
FR2885050A1 (fr) | Composition amincissante a base d'extraits de cacao. | |
FR3013979A1 (fr) | Composition comprenant des extraits de raisin tannat ou cannoneau, procede d'extraction et utilisations | |
EP3052198B1 (fr) | Composition huileuse contenant un extrait d'hemerocalle et utilisations | |
FR2703601A1 (fr) | Emulsion du type huile dans eau contenant du lait. | |
FR2895257A1 (fr) | Actif pour le traitement du contour des yeux. | |
FR2894483A1 (fr) | Composition cosmetique a base d'huiles et leurs utilisations dans le soulagement des douleurs. | |
EP3191106B1 (fr) | Composition comprenant une microalgue enrichie en silicium pour une utilisation therapeutique | |
LU85411A1 (fr) | Compositions et procede pour stabiliser l'anthraline | |
FR2875134A1 (fr) | Utilisation cosmetique d'une composition renfermant un derive ascorbique et des particules de polyamide | |
FR3123807A1 (fr) | Serum cosmetique activateur et utilisation dans un procede de soin cosmetique | |
JPH0551312A (ja) | 複合ビタミン配合化粧料 | |
EP4009940A1 (fr) | Nouvelle utilisation cosmétique d'un extrait d'epilobium angustifolium | |
FR3112487A1 (fr) | Extrait huileux d’hibiscus et ses utilisations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004/06128 Country of ref document: ZA Ref document number: 200406128 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003565524 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 163365 Country of ref document: IL Ref document number: 2475218 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003717383 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003717383 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10503360 Country of ref document: US |